At the Society for Laboratory Automation and Screening (SLAS) International Conference and Exhibition in Boston, MA, Depixus was awarded the Ignite Award for their innovative MAGNA™ technology. This accolade recognized the company as a pioneer in interactomics and highlighted their game-changing approach to life sciences research.
Depixus was one of 16 companies selected to participate in the SLAS2024 Innovation AveNEW program, which showcased cutting-edge technologies that have the potential to revolutionize scientific research. The top eight companies from this program were shortlisted as finalists for the Ignite Award, and Depixus was honored to be recognized among them.
The MAGNA One™ instrument is based on magnetic force spectroscopy, allowing high-throughput analysis of dynamic biomolecular interactions. This technology is unique in its ability to provide direct, simultaneous, and real-time measurements from thousands of individual molecules, making it particularly useful for exploring challenging targets such as RNA and protein-protein interactions. These insights can accelerate the development of novel therapeutics and deepen our understanding of disease mechanisms.
Gordon Hamilton, CEO of Depixus, expressed his excitement about winning the Ignite Award and thanked all those involved in making it happen. He emphasized the importance of this recognition in advancing scientific knowledge and helping to develop new treatments for diseases where they are urgently needed. Steve Klose, Chief Commercial Officer of Depixus, highlighted the timing of this award with the launch of their technology access program and commercial rollout of MAGNA One. Klose expressed excitement for scientists worldwide to put this innovative instrument to work to transform research outcomes. For more information about Depixus’s products and services visit depixus.com